Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Tamoxifen reduces the risk of benign breast disease

19.02.2003


Tamoxifen appears to reduce the risk of benign breast disease and may result in fewer biopsies, according to an analysis of data from a major randomized clinical trial of tamoxifen. The findings appear in the February 19 issue of the Journal of the National Cancer Institute.



Tamoxifen was shown in the Breast Cancer Prevention Trial to reduce the incidence of invasive and noninvasive breast cancer by as much as 50% compared to placebo. Other studies have suggested that tamoxifen can also decrease the size of benign breast lesions, which have been associated with a modest increase in the risk for developing invasive breast cancer.

To examine the effect of tamoxifen on the risk of developing benign breast lesions, Elizabeth Tan-Chiu, M.D., of the Cancer Research Network in Plantation, Fla., and her coworkers from the National Surgical Adjuvant Breast and Bowel Project examined the incidence of benign breast disease among 13,203 women treated with either tamoxifen or a placebo as part of the Breast Cancer Prevention Trial. The authors also noted how many biopsies each group of women underwent.


Overall, tamoxifen treatment reduced the risk of benign breast disease by 28%. Women in the tamoxifen group were less likely to develop several types of benign diseases--adenosis, cysts, duct ectasia, fibrocystic disease, hyperplasia, and metaplasia--than women in the placebo group. Tamoxifen therapy also reduced the risk of fibroadenoma and fibrosis--two conditions that often result in biopsies. In fact, women in the tamoxifen group underwent 29% fewer biopsies than women in the placebo group. The authors note that the reduction in risk was mostly seen in women younger than age 50.

The authors conclude that, in the Breast Cancer Prevention Trial, "tamoxifen not only reduced the risk of invasive and noninvasive breast cancer but also reduced the risk of benign breast disease and the morbidity and costs of repeated diagnosis and treatment that are associated with it."

They point out, however, that tamoxifen treatment carries risks, such as stroke and endometrial cancer, and they add that they do not advocate the indiscriminate use of tamoxifen for the treatment of benign breast disease.



Contact: Lori Garvey, National Surgical Adjuvant Breast and Bowel Project, 412-330-4621; fax: 412-330-4645, lori.garvey@nsabp.org

Tan-Chiu E, Wang J, Costantino JP, Paik S, Butch C, Wickerham DL, et al. Effects of tamoxifen on benign breast disease in women at high risk for breast cancer. J Natl Cancer Inst 2003;95:302–7.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage.

Linda Wang | EurekAlert!
Further information:
http://jncicancerspectrum.oupjournals.org/

More articles from Health and Medicine:

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

nachricht The gut microbiota plays a key role in treatment with classic diabetes medication
01.06.2017 | University of Gothenburg

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

Im Focus: Optoelectronic Inline Measurement – Accurate to the Nanometer

Germany counts high-precision manufacturing processes among its advantages as a location. It’s not just the aerospace and automotive industries that require almost waste-free, high-precision manufacturing to provide an efficient way of testing the shape and orientation tolerances of products. Since current inline measurement technology not yet provides the required accuracy, the Fraunhofer Institute for Laser Technology ILT is collaborating with four renowned industry partners in the INSPIRE project to develop inline sensors with a new accuracy class. Funded by the German Federal Ministry of Education and Research (BMBF), the project is scheduled to run until the end of 2019.

New Manufacturing Technologies for New Products

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Innovative LED High Power Light Source for UV

22.06.2017 | Physics and Astronomy

Mathematical confirmation: Rewiring financial networks reduces systemic risk

22.06.2017 | Business and Finance

Spin liquids − back to the roots

22.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>